Clinical Trials Logo

Clinical Trial Summary

What is the difference between the use of one drug (Oral Metronidazole) versus the use of this same drug combined with another drug (Rifampin) in treatment of bacteria and infection-associated diarrhea in patients? This infection is an important cause of morbidity and mortality in both the community and hospitals, and the leading cause of hospital and chronic facility-acquired diarrhea. Research is important for the treatment of this infection. Patient care with use of two medication treatment regimens will be studied.


Clinical Trial Description

Clostridium difficile infection contributes to both community and hospital acquired morbidity and mortality. Metronidazole alone is usually considered the drug of choice, however, frequent relapses occur at a rate of 10-40%. The purpose of this study is to address the use of a combined drug regimen treatment (Metronidazole and Rifampin) for the treatment of CDAD. These drugs used together have been successful. Objectives are to determine the time (days) to resolution of symptoms in each treatment arm; to measure clinical relapse rates; and to assess adverse reactions related to treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00182429
Study type Interventional
Source McMaster University
Contact
Status Completed
Phase Phase 3
Start date February 2004
Completion date December 31, 2005

See also
  Status Clinical Trial Phase
Completed NCT03181516 - Efficacy and Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Children on Antibiotics Phase 2
Recruiting NCT03895593 - Rescue Fecal Microbiota Transplantation for National Refractory Intestinal Infections
Completed NCT00382304 - A Study of the Absorption of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea Phase 2
Completed NCT04212403 - Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB) N/A
Terminated NCT02900196 - Effect of a Fresh Fermented Dairy Drink Product Consumption on Antibiotic Associated Diarrhea and Gastro-Intestinal Disorders N/A
Completed NCT01782755 - Probiotics: Prevention of Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT): A Feasibility Clinical Trial Phase 2
Completed NCT06109740 - Probiotics For The Prevention of Antibiotics Associated Diarrhea in the Pediatric Intensive Care Unit N/A
Suspended NCT00591357 - Efficacy of Loperamide for C. Difficile Colitis and Other Diarrheal Diseases Associated With Antibiotic Therapy Phase 4
Completed NCT00700557 - Probiotics at the Treatment of Antibiotic Associated Diarrhea Phase 4
Active, not recruiting NCT03256708 - Prevention of Antibiotic-Associated Diarrhoea With Prolardii N/A
Completed NCT04321460 - Study of LRG-002 Hard Capsules (Lek d.d., Slovenia) Used in the Prophylaxis of Antibiotic-associated Diarrhea in Adults. Phase 3
Completed NCT05607056 - Efficacy and Safety of Sinquanon for Prevention of Antibiotic-associated Diarrhea in Adults N/A
Recruiting NCT05845073 - The Efficacy of a Probiotic for Antibiotic Associated Gastrointestinal Symptoms N/A
Completed NCT01143623 - Dose Response Effect of Probiotics for the Prevention of Antibiotic-associated Diarrhea in Chinese Adults Phase 2/Phase 3
Completed NCT02127814 - Lactobacillus Reuteri in the Prevention of Antibiotic Associated-diarrhea and Clostridium Difficile N/A
Completed NCT00641199 - Probiotics for Prevention of Antibiotic-associated Diarrhea N/A
Completed NCT02462590 - Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial Phase 4
Terminated NCT01143272 - Probiotic Saccharomyces Boulardii for the Prevention of Antibiotic-associated Diarrhoea Phase 3
Completed NCT03755765 - Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics Early Phase 1
Completed NCT05990972 - Clinical Study of Fecal Microbiota Transplantation in the Treatment of Antibiotic-associated Diarrhea N/A